3NCCLS. EP5-A2: Evalution of precision performance of quantitative mea- surement methods; approved guideline-second edition [ S]. Wayne PA, 2004.
4NCCLS. EP7-A2: Interference testing in clinical chemistry; approved guideline-second edition[ S ]. Wayne PA, 2005.
5NCCLS. EP17-A: Protocols for determination of dimits of detection and dimits of duantization; Approved Guideline-Second Edition [ S ]. Wayne PA, 2004.
6NCCLS. EP6-A: Evalution of file linearity of quantitative measurement procedures: A statistical approach; Approved guideline [ S ]. Wayne PA, 2003.
7NCCLS. C28-A2: How to define and determine reference intervals in the clinical laboratory[ S]. Wayne PA, 2000.
8MeGany JD. Banding lecture 2001, Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes[J]. Diabetes,2002,51 ( 1 ) :7.
6Santomauro AT, Bodem G, Silva ME, et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects[J]. Diabetes, 1999,48:1836.
7Boden G, Role of fatty acids in the pathogenesis of insulin resistance and NIDDM[J], Diabetes, 1997,46:3.
8Shimabukuro M,Zhou YT, Levi M, Unger RH. Fatty acid- induced cell apoptosis:A link between obesity and diabetes[J]. Proc Natl Acad Sci, 1998,95:2498.
9Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: Genetic and clinical implications[ J]. Diabetes, 1995,44 : 863.
8Fraser CG,Harris EK. Generation and application of data on biological variation in clinical chemistry[J].{H}Critical Reviews in Clinical Laboratory Sciences,1989,(05):409-437.
9Widjaja A,Morris RJ,Levy JC. Within-and between-subject variation in commonly measured anthropometric and biochemical variables[J].{H}Clinical Chemistry,1999,(04):561-566.
